Anwei Lu
Overview
Explore the profile of Anwei Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang C, Wang Q, Lu A
Eur J Med Res
. 2024 Dec;
29(1):628.
PMID: 39726046
Background: With the shift in donor lung allocation from blood type and waiting order to the use of the lung allocation score (LAS) system, there are increasingly more cases of...
2.
Ye Y, Lian R, Li Z, Chen X, Huang Y, Yao J, et al.
BMC Cancer
. 2024 Aug;
24(1):1005.
PMID: 39138415
Background: To identify the cut-off values for the number of metastatic lymph nodes (nMLN) and lymph node ratio (LNR) that can predict outcomes in patients with FIGO 2018 IIICp cervical...
3.
Zhong S, Guo Q, Chen X, Luo X, Long Y, Chong T, et al.
Int J Biol Sci
. 2024 Jan;
20(3):916-936.
PMID: 38250152
The lipid synthesis of fatty acid (FA) represents a significant hallmark in the occurrence and progression of malignant tumor, which are associated with lymph node (LN) metastasis. Elucidation of the...
4.
Cao X, Qiu Y, Peng Z, Chen L, Zhou L, Lu A, et al.
BMC Med Imaging
. 2023 Oct;
23(1):170.
PMID: 37904129
Objective: This study explored using an improved ultrasound (US) for quantitative evaluation of the degree of pelvic organ prolapse(POP). Design: A transluminal probe was used to standardize ultrasound imaging of...
5.
Chen X, Hao Y, Liu Y, Zhong S, You Y, Ao K, et al.
Adv Sci (Weinh)
. 2023 Oct;
10(32):e2302705.
PMID: 37818745
Immunotherapy has recently emerged as the predominant therapeutic approach for cervical cancer (CCa), driven by the groundbreaking clinical achievements of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies. N4-acetylcytidine (ac4C)...
6.
Li P, Liu J, Wang L, Kang S, Yang Y, Guo J, et al.
Front Surg
. 2021 Sep;
8:692163.
PMID: 34557515
To examine the association between surgical volume and surgical and oncological outcomes of women with stage IB1 cervical cancer who underwent laparoscopic radical hysterectomy (LRH). We retrospectively analyzed the oncological...
7.
Li Z, Chen C, Liu P, Lu A, Zhao H, Zhan X, et al.
Arch Gynecol Obstet
. 2021 Aug;
305(2):449-458.
PMID: 34406459
Purpose: To compare oncological outcomes of laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) for low-risk cervical cancer. Method: We retrospectively compared the 3-year overall survival (OS) and 3-year...
8.
Li P, Fang Z, Li W, Hao M, Wang W, Kang S, et al.
Eur J Surg Oncol
. 2020 Sep;
47(5):1069-1074.
PMID: 32980212
Objective: To assess the impact of neoadjuvant chemotherapy on postoperative pathology for stage IB2 and IIA2 cervical squamous cell carcinoma. Methods: Postoperative pathology was compared between patients who received neoadjuvant...
9.
Liu P, Liang C, Lu A, Chen X, Liang W, Li D, et al.
Gynecol Oncol
. 2020 Jun;
158(2):294-302.
PMID: 32507516
Objective: The primary objective was to describe the incidence and risk factors of urologic complications during radical hysterectomy for cervical cancer. The secondary objective was to investigate the impact of...
10.
Hao Y, Xiao Y, Zhang Z, Zhao H, Zhou W, Guo X, et al.
Biomed Pharmacother
. 2019 Dec;
121:109643.
PMID: 31810133
Objectives: In Uighur medicine, abnormal Savda Munziq (AMSq) is an adjuvant therapy for cancer patients with abnormal Savda syndrome (ASS) who exhibit the highest degree of pathogenicity and malignancy. The...